Alejandro Menchaca, JD


The Inner Workings of the BPCIA Patent Dance

The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples show.

Kristi Rosa


BLA Resubmitted to FDA for On-Body Injector Presentation of Pegfilgrastim-cbqv

The biologics license application (BLA) seeking the approval of the on-body injector presentation of pegfilgrastim-cbqv, a biosimilar of Neulasta Onpro, has been resubmitted to the FDA for review.

University of Arizona R. Ken Coit College of Pharmacy


Dr Ivo Abraham Column: Biosimilars and the Commoditization of Treatments

Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, explores whether biosimilars should be considered a commodity and if the commodification of medications is sustainable as the market continues to expand.

© 2024 MJH Life Sciences

All rights reserved.